Fujirebio introduces its Neuro Expert Toolbox (NExT) at AAIC 2025

Fujirebio is introducing its Neuro Expert Toolbox (NExT) for the first time at AAIC 2025 (Alzheimer's Association International Conference®) in Toronto, Canada July 27 to 31, 2025. 

NExT is an innovative framework that enables partners and customers to access Fujirebio's deep expertise for every stage of their neuro fluid biomarker testing needs, from an early concept and exploratory research to clinical research and validated diagnostic solutions.

For over three decades, Fujirebio has been at the forefront of Alzheimer’s disease (AD) diagnostics, pioneering breakthrough solutions that have transformed our understanding of the disease and the way AD is being diagnosed. Today, in an age where early diagnosis and personalized treatment are becoming increasingly crucial, Fujirebio stands as the trusted expert partner, offering unique capabilities from early biomarker research to routine clinical testing. NExT enables stakeholders to tap into Fujirebio’s unmatched expertise and infrastructure across all phases of the biomarker lifecycle.  

 
Fujirebio, a complete partner across the development journey

Fujirebio's expertise in the field of neurological disease testing spans the entire biomarker development pathway. The Neuro Expert Toolbox crystallizes these multiple capabilities into different stages (or chambers) of the pathway:

• Concept chamber: Working closely with academic institutions and pharmaceutical partners, Fujirebio helps identify and validate promising new biomarkers. Our collaborative approach means we are often involved in groundbreaking research years before potential clinical applications emerge. Fujirebio takes a platform-agnostic, biology-first approach, allowing for flexible and pathophysiology-relevant assay development.
• Explorer chamber: The Lumipulse® G based RUO (Research Use Only) Xplorer kits can be measured via selected partners and enable rapid evaluation of novel biomarkers' clinical potential on a robust platform. This accelerates the pathway from discovery to application, helping partners, such as pharmaceutical companies and research institutions, make faster, more informed decisions about possible biomarker utility.
• Incubation chamber: With an extensive menu of RUO assays, Fujirebio supports evaluations of novel biomarkers by any user of the automated LUMIPULSE G platform. This robust technology foundation is crucial for establishing potential clinical validity and utility before deciding the regulatory strategy.
• Routine chamber: When biomarkers prove their clinical value, Fujirebio's regulatory expertise and global reach enable broad market access into routine clinical applications. We have a solid track record within the neuro field of successful in vitro diagnostics (IVD) product development and commercialization in many regions across the world.  

Are you interested in hearing more about how Fujirebio’s unique combination of vision, platform flexibility, and expertise in the field of testing for neurological disorders can support your work? 

Visit Fujirebio at AAIC 2025 – booth #622 – or click here for more information.